Vertex licenses Editas’ gene editing technology in $100m deal
The payment, which encompasses newly approved Casgevy, is the latest deal in a long line of CRISPR licensing twists and turns.
The payment, which encompasses newly approved Casgevy, is the latest deal in a long line of CRISPR licensing twists and turns.
What's Your Reaction?
